Biotech Due Diligence › Metrics › Pre-Seed
Key Metrics for Biotech Startups at Pre-Seed Stage: Investor Benchmarks
These 4 metrics are what institutional investors evaluate when screening Biotech startups at the Pre-Seed stage. Each metric is accompanied by benchmark ranges sourced from our database of 2+ comparable company analyses.
Pre-Seed Stage Traction Expectation: Pre-revenue acceptable. Early customers, LOIs, or clear path to first $1K MRR most competitive.
Metrics Expected at Pre-Seed: Customer interviews (10+), Pilot LOIs, Waitlist size, Early MRR (optional at this stage)
Metrics Expected at Pre-Seed: Customer interviews (10+), Pilot LOIs, Waitlist size, Early MRR (optional at this stage)
01. Clinical Stage
IND Filed → Phase I → Phase II → Phase III → FDA Submission
Each stage transition is a major de-risking milestone
Pre-Seed context: At Pre-Seed stage ($250K–$2M), this metric is the primary evaluation criterion. Pre-revenue acceptable. Early customers, LOIs, or clear path to first $1K MRR most competitive.
02. Target Patient Population
Rare disease: >200K US patients | Broad indication: millions
Rare disease (orphan) designation offers faster FDA path and market exclusivity
Pre-Seed context: At Pre-Seed stage ($250K–$2M), this metric is the primary evaluation criterion. Pre-revenue acceptable. Early customers, LOIs, or clear path to first $1K MRR most competitive.
03. Preclinical Efficacy Data
In vivo (animal) studies with validated disease models
In vitro data alone is insufficient for investment decisions
Pre-Seed context: At Pre-Seed stage ($250K–$2M), this metric is a secondary signal. Pre-revenue acceptable. Early customers, LOIs, or clear path to first $1K MRR most competitive.
04. IP Protection
Core composition-of-matter patents with >10 years of exclusivity
Patent expiry timeline determines commercial window
Pre-Seed context: At Pre-Seed stage ($250K–$2M), this metric is a secondary signal. Pre-revenue acceptable. Early customers, LOIs, or clear path to first $1K MRR most competitive.
How DDR Benchmarks These Metrics
When you upload a Biotech startup pitch deck, DDR automatically:
- Extracts all Biotech metrics from every slide of the pitch deck
- Benchmarks each metric against 2 comparable Biotech companies
- Flags metrics outside healthy ranges as red flags with severity weighting
- Provides an overall verdict (INVEST / DIG DEEPER / PASS) with score 1–10
- Generates expected return scenarios based on Biotech exit data
Biotech Due Diligence — All Guides
AUTOMATE YOUR BIOTECH DUE DILIGENCE
Screen Any Biotech Startup in 5 Minutes
Upload a pitch deck PDF and DDR automatically runs this full due diligence framework — 13 OSINT sources, founder verification, all sector-specific red flags, comparable company analysis, and INVEST/PASS verdict.
GET YOUR FREE SCAN →